Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Fulcrum Therapeutics Inc shares valued at $58,377,021 were sold by RA CAPITAL MANAGEMENT, L.P. on Dec 08 ’25. At $13.98 per share, RA CAPITAL MANAGEMENT, L.P. sold 4,175,139 shares. The insider’s holdings dropped to 6,053,960 shares worth approximately $83.54 million following the completion of this transaction.
Also, RA Capital Healthcare Fund LP purchased 4,175,139 shares, netting a total of over 54,235,056 in proceeds.
Before that, Gould Robert J had sold 15,000 shares from its account. In a trade valued at $165,495, the Director traded Fulcrum Therapeutics Inc shares for $11.03 each. Upon closing the transaction, the insider’s holdings decreased to 15,000 shares, worth approximately $6.69 million.
As published in their initiating research note from Truist on November 24, 2025, Fulcrum Therapeutics Inc [FULC] has been a Buy. Analysts at H.C. Wainwright upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late July. As of May 23, 2025, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for FULC. Earlier on May 15, 2025, Cantor Fitzgerald upgraded its rating. Their new recommendation was “an Overweight” for FULC stock which previously was a “a Neutral”.
Analyzing FULC Stock Performance
On last trading session, Fulcrum Therapeutics Inc [NASDAQ: FULC] plunged -5.48% to $13.8. The stock’s lowest price that day was $13.44, but it reached a high of $15.32 in the same session. During the last five days, there has been a surge of approximately 52.32%. Over the course of the year, Fulcrum Therapeutics Inc shares have jumped approximately 245.86%. Shares of the company reached a 52-week high of $15.74 on 12/08/25 and a 52-week low of $2.32 on 04/07/25.
Support And Resistance Levels for Fulcrum Therapeutics Inc (FULC)
According to the 24-hour chart, there is a support level at 13.03, which, if violated, would cause prices to drop to 12.25. In the upper region, resistance lies at 14.95. The next price resistance is at 16.09. RSI (Relative Strength Index) is 67.26 on the 14-day chart, showing neutral technical sentiment.
Is Fulcrum Therapeutics Inc subject to short interest?
Stocks of Fulcrum Therapeutics Inc saw a sharp rise in short interest on 2025-11-28 jumping by 0.28 million shares to 3.81 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 3.53 million shares. A jump of 7.39% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.25 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.25.
Which companies own the most shares of Fulcrum Therapeutics Inc (FULC)?
In terms of Fulcrum Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 23 in the next 12 months, up nearly 57.53% from the previous closing price of $14.6. Analysts anticipate Fulcrum Therapeutics Inc stock to reach 25 by 2025, with the lowest price target being 10. In spite of this, 13 analysts ranked Fulcrum Therapeutics Inc stock as Buy at the end of 2025. On September 13, 2024, H.C. Wainwright assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
